Skip to content

Study · Non-randomized trial · n = 13 · 2021

5 results

Testing the effects of the GLP-1 receptor agonist exenatide on cocaine self-administration and subjective responses in humans with cocaine use disorder.

Angarita GA, Matuskey D, Pittman B, Costeines JL, Potenza MN, Jastreboff AM, Schmidt HD, Malison RT

Drug and alcohol dependence15 Feb 2021Cited by 66 (Europe PMC)

PMID33621809 (opens in a new tab)PMCIDPMC8026565 (opens in a new tab)DOI10.1016/j.drugalcdep.2021.108614 (opens in a new tab)PepBankPUB-33621809
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In people with cocaine use disorder, exenatide did not change cocaine infusions versus placebo.

    In plain wordsIn people with cocaine use disorder, exenatide did not change cocaine use during testing compared with placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeCocaine infusions
    Study

    n = 13

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Patterns of use · Mental health and mood
    Studied dose
    5 mcg · subcutaneous · acute pretreatmentAs given in this study (human).

    Measurements

    Cocaine infusions
    8.5 infusions
    exenatide pretreatment
    Cocaine infusions
    9.1 infusions
    placebo pretreatment

    Source sentences

    Summary
    Acute pretreatment with exenatide versus placebo did not change cocaine infusions (8.5 ± 1.2 vs. 9.1 ± 1.2; p = 0.39), self-reported euphoria (4.4 ± 0.8 vs. 4.1 ± 0.8; p = 0.21), or wanting of cocaine (5.6 ± 0.9 vs. 5.4 ± 0.9; p = 0.46).
    2 context sentences
    Summary · context
    Non-treatment-seeking CUD subjects underwent two human laboratory cocaine self-administration test sessions following an acute 3 -h pre-treatment with exenatide (5 mcg; subcutaneously) or placebo.
    Summary · context
    Thirteen individuals completed the study.
  2. 02HumanNon-randomized trialEfficacy outcome

    In people with cocaine use disorder, exenatide did not change self-reported euphoria versus placebo.

    In plain wordsIn people with cocaine use disorder, exenatide did not change reported euphoria compared with placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeEuphoria
    Study

    n = 13

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Patterns of use · Mental health and mood
    Studied dose
    5 mcg · subcutaneous · acute pretreatmentAs given in this study (human).

    Measurements

    Self-reported euphoria
    4.4 VAS rating
    exenatide pretreatment
    Self-reported euphoria
    4.1 VAS rating
    placebo pretreatment

    Source sentences

    Summary
    Acute pretreatment with exenatide versus placebo did not change cocaine infusions (8.5 ± 1.2 vs. 9.1 ± 1.2; p = 0.39), self-reported euphoria (4.4 ± 0.8 vs. 4.1 ± 0.8; p = 0.21), or wanting of cocaine (5.6 ± 0.9 vs. 5.4 ± 0.9; p = 0.46).
    2 context sentences
    Summary · context
    Non-treatment-seeking CUD subjects underwent two human laboratory cocaine self-administration test sessions following an acute 3 -h pre-treatment with exenatide (5 mcg; subcutaneously) or placebo.
    Summary · context
    Thirteen individuals completed the study.
  3. 03HumanNon-randomized trialEfficacy outcome

    In people with cocaine use disorder, exenatide did not change wanting cocaine versus placebo.

    In plain wordsIn people with cocaine use disorder, exenatide did not change the desire for cocaine compared with placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeWanting cocaine
    Study

    n = 13

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Patterns of use · Mental health and mood
    Studied dose
    5 mcg · subcutaneous · acute pretreatmentAs given in this study (human).

    Measurements

    Wanting of cocaine
    5.6 VAS rating
    exenatide pretreatment
    Wanting of cocaine
    5.4 VAS rating
    placebo pretreatment

    Source sentences

    Summary
    Acute pretreatment with exenatide versus placebo did not change cocaine infusions (8.5 ± 1.2 vs. 9.1 ± 1.2; p = 0.39), self-reported euphoria (4.4 ± 0.8 vs. 4.1 ± 0.8; p = 0.21), or wanting of cocaine (5.6 ± 0.9 vs. 5.4 ± 0.9; p = 0.46).
    2 context sentences
    Summary · context
    Non-treatment-seeking CUD subjects underwent two human laboratory cocaine self-administration test sessions following an acute 3 -h pre-treatment with exenatide (5 mcg; subcutaneously) or placebo.
    Summary · context
    Thirteen individuals completed the study.
  4. 04HumanNon-randomized trialEfficacy outcome

    In people with cocaine use disorder, exenatide reduced GLP-1 levels versus placebo.

    In plain wordsIn people with cocaine use disorder, exenatide lowered GLP-1 levels compared with placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseGLP-1 levels
    Study

    n = 13

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Endogenous peptide levels · Endocrine and hormones
    Studied dose
    5 mcg · subcutaneous · acute pretreatmentAs given in this study (human).

    Source sentences

    Summary
    Exenatide vs. placebo reduced levels of GLP-1 (p = 0.03) and insulin (p = 0.02).
    2 context sentences
    Summary · context
    Non-treatment-seeking CUD subjects underwent two human laboratory cocaine self-administration test sessions following an acute 3 -h pre-treatment with exenatide (5 mcg; subcutaneously) or placebo.
    Summary · context
    Thirteen individuals completed the study.
  5. 05HumanNon-randomized trialEfficacy outcome

    In people with cocaine use disorder, exenatide reduced insulin levels versus placebo.

    In plain wordsIn people with cocaine use disorder, exenatide lowered insulin levels compared with placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseInsulin levels
    Study

    n = 13

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Endogenous peptide levels · Endocrine and hormones
    Studied dose
    5 mcg · subcutaneous · acute pretreatmentAs given in this study (human).

    Source sentences

    Summary
    Exenatide vs. placebo reduced levels of GLP-1 (p = 0.03) and insulin (p = 0.02).
    2 context sentences
    Summary · context
    Non-treatment-seeking CUD subjects underwent two human laboratory cocaine self-administration test sessions following an acute 3 -h pre-treatment with exenatide (5 mcg; subcutaneously) or placebo.
    Summary · context
    Thirteen individuals completed the study.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.